{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:22:51Z","timestamp":1760188971661},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":6602,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1990,6]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>Ten patients (seven women, three men) with active acromegaly, five previously treated and five newly diagnosed, were included in an open\u2010label prospective trial of 3 daily subcutaneous injections of the long\u2010acting somatostatin analogue SMS 201\u2010995 (Sandostatin) at increasing doses in order to obtain maximum growth hormone (GH) suppression. Four patients had received surgery, radiotherapy or bromocriptine. SMS 201\u2010995 doses were increased in a stepwise fashion from 100 \u03bcg every 8 h (three times daily) to 200, 300 and finally 500 \u03bcg three times daily at monthly intervals if mean serum GH values failed to decrease to undetectable levels in over 75% of the samples. The optimal dose was maintained for up to 28 months. Significant clinical improvement of headache, soft tissue swelling, facial features, hyperhidrosis and paraesthesia occurred in all patients. Mean 12\u2010h GH levels were significantly suppressed in four patients and fell to normal values in four. Suppression of GH levels was not achieved in two patients. Comparison of the mean interindividual GH values shows that the optimal efficacious dose is 100 \u03bcg t. i. d. in 7\/10 patients. Somatomedin\u2010C (SM\u2010C) was also significantly reduced to below 50% of pretreatment levels in nine patients in whom it was measured. The subsequent increments of SMS 201\u2010995 up to 500 \u03bcg three times daily did not produce further clinically relevant GH or SM\u2010C suppression. Pituitary tumour shrinkage occurred in five patients. Thyroid function remained normal. Impaired glucose tolerance occurred in four patients. Side\u2010effects (diarrhoea, abdominal discomfort) were mild and transient. Asymptomatic gallstones occurred in three patients on 1500 \u03bcg\/day and one patient on 600 \u03bcg\/day after 6\u201012 months treatment. This dose\u2010finding study shows that 100 \u03bcg three times daily SMS 201\u2010995 is an effective therapy for most of the acromegalic patients we treated.<\/jats:p>","DOI":"10.1111\/j.1365-2265.1990.tb00916.x","type":"journal-article","created":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T11:12:54Z","timestamp":1205752374000},"page":"695-705","source":"Crossref","is-referenced-by-count":17,"title":["CLINICAL AND BIOCHEMICAL EFFECTS OF INCREMENTAL DOSES OF THE LONG\u2010ACTING SOMATOSTATIN ANALOGUE SMS 201\u2010995 IN TEN ACROMEGALIC PATIENTS"],"prefix":"10.1111","volume":"32","author":[{"given":"Y. F.","family":"SHI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. G.","family":"HARRIS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X. F.","family":"ZHU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Y.","family":"DENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-66-1-16"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-6-856"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(82)90087-X"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5945.622"},{"key":"e_1_2_1_6_1","first-page":"132","article-title":"Growth hormone release inhibiting hormone in acromegaly","author":"Besser G. M.","year":"1974","journal-title":"British Medical Journal"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.290.6464.284-a"},{"key":"e_1_2_1_8_1","first-page":"129","article-title":"Radioimmunoassay of serum growth hormone","volume":"4","author":"Deng J. Y.","year":"1981","journal-title":"Chinese Journal of Medical Laboratory Technology"},{"key":"e_1_2_1_9_1","first-page":"202","article-title":"Radioimmunoassay of Somatomedin C","volume":"4","author":"Gao S. M.","year":"1988","journal-title":"Chinese Journal of Endocrinology and Metabolism"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365528609087433"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180984"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365528609087442"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198512193132504"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90706-2"},{"issue":"287","key":"e_1_2_1_15_1","first-page":"107","article-title":"Long\u2010term effectiveness of the somatostatin analog SMS 201\u2010995 in the treatment of acromegaly","volume":"117","author":"Pl\u00f6ckinger U.","year":"1988","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-68-4-844"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-62-4-729"},{"key":"e_1_2_1_18_1","first-page":"80","article-title":"Somatostatinoma syndrome: does a clinical entity exist","volume":"102","author":"Stacpoole W.","year":"1983","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180983"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365528609087443"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1986.65.1.0037"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.293.6558.1327"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365528609087441"},{"key":"e_1_2_1_24_1","first-page":"841","volume-title":"Textbook of Gastroenterology","author":"Zheng Z. T.","year":"1986"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.1990.tb00916.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.1990.tb00916.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T03:36:53Z","timestamp":1698032213000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.1990.tb00916.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1990,6]]}},"alternative-id":["10.1111\/j.1365-2265.1990.tb00916.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.1990.tb00916.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,6]]}}}